Thrombocytopenia

Slide 1 · Thrombocytopenia

Mechanisms of reduced platelet number and clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Recognize

Define thrombocytopenia; Correlate platelet-count ranges with characteristic bleeding patterns.

Explain

Trace how impaired platelet plug formation promotes mucocutaneous and small-vessel hemorrhage.

Classify

Discriminate reduced production, shortened survival, sequestration, and dilution.

Interpret

Use platelet counts, blood smear review, PT/PTT, and clinical context without overinterpreting a single test.

Slide 3 · The hemostatic response has two linked phases

Vascular injury

Loss of normal endothelial integrity exposes a surface requiring hemostatic repair.

Primary hemostasis

Platelets adhere and aggregate, forming an initial platelet plug.

Secondary hemostasis

Platelets support coagulation reactions, permitting a fibrin clot.

Slide 4 · The bleeding phenotype depends on the affected component

Vessel wall

Structural fragility can permit hemorrhage with normal platelet tests.

Platelet number / function

Defective primary hemostasis favors skin and mucosal bleeding.

Coagulation factors

Abnormal fibrin-generating pathways are assessed by PT and PTT.

Slide 5 · Primary hemostasis: How a platelet plug forms

Adhesion

Circulating platelets attach at sites of vascular injury.

Aggregation

Additional platelets bind to one another at the damaged site.

Initial hemostatic plug

The recruited platelet mass begins to seal the injured microvessel.

Slide 6 · Platelets also facilitate secondary hemostasis

Platelet recruitment

Activated platelets accumulate at the site of injury.

Coagulation support

Platelet surfaces promote key reactions of the clotting cascade.

Fibrin formation

Coagulation reinforces the initial platelet plug with fibrin.

Slide 7 · Definition of thrombocytopenia

<150,000/μL

Platelet-count threshold

A count below 150 × 10³ platelets/μL to define thrombocytopenia. The chapter gives an approximate laboratory reference range of 150–350 × 10³/μL. A low count identifies a numerical abnormality, not its mechanism.

Slide 8 · Platelet counts and bleeding context

150–350 × 10³/μL

Laboratory reference interval cited in the chapter.

20–50 × 10³/μL

Counts in this band can aggravate posttraumatic bleeding.

<20 × 10³/μL

May be associated with spontaneous, nontraumatic bleeding.

Slide 9 · Why low counts amplify bleeding after injury

A hemostatic challenge reveals limited reserve

After trauma, effective hemostasis requires rapid recruitment and aggregation of sufficient platelets. With markedly reduced circulating platelet numbers, the primary plug may be inadequate even when coagulation factors are intact.

20–50 × 10³/μL as a range that can aggravate posttraumatic bleeding.

Slide 10 · Spontaneous bleeding at profound platelet depletion

A very low count may permit bleeding without trauma

Intact small vessels experience minor physiological stresses. Profound thrombocytopenia reduces the capacity to seal microvascular defects, so hemorrhage may occur without a preceding recognized injury.

A count below 20 × 10³/μL may be associated with spontaneous bleeding.

Slide 11 · Why microvascular bleeding is characteristic

Small-vessel disruption

Frequent small-scale vascular breaches require rapid local sealing.

Reduced platelet plug

A depleted platelet pool compromises the initial platelet response.

Mucocutaneous hemorrhage

Bleeding becomes evident in skin and exposed mucosal surfaces.

Slide 12 · Cutaneous bleeding: Recognition and meaning

Petechiae

Small pinpoint hemorrhages may appear in the skin as platelet-dependent hemostasis fails. Dependent areas can be especially prominent in platelet-destructive syndromes.

Purpura / ecchymoses

Confluent or larger areas of cutaneous bleeding reflect hemorrhage into the tissue. The pattern indicates bleeding, but does not identify the causal mechanism.

Slide 13 · Mucosal sites commonly affected

Gastrointestinal tract

Bleeding may involve gastrointestinal mucosal surfaces; Melena is described in the adjacent immune-thrombocytopenia section.

Genitourinary tract

Hematuria and excessive menstrual bleeding may reflect mucosal hemorrhage associated with platelet depletion.

Oral / nasal mucosa

Gingival bleeding and epistaxis occur in thrombocytopenic bleeding syndromes.

Slide 14 · Intracranial bleeding is the feared complication

Profound thrombocytopenia can threaten the central nervous system

Spontaneous hemorrhage is usually mucocutaneous, but intracranial bleeding is the complication of greatest concern in patients with markedly depressed platelet counts. Recognizing this consequence is a core clinical implication of the count.

Critical site: Intracranial hemorrhage

Slide 15 · Isolated thrombocytopenia and coagulation tests

Platelet count

Reduced below the reference interval. The numerical abnormality affects the primary hemostatic plug and platelet contribution to clot formation.

PT and PTT

Typically normal when thrombocytopenia is isolated; These tests measure coagulation pathway activity rather than platelet number.

Slide 16 · Prothrombin time: What it evaluates

Assay principle

Coagulation is timed after tissue thromboplastin and calcium are added to plasma.

Pathway interrogated

PT assesses extrinsic and common pathways; Relevant factors include VII, X, V, prothrombin, and fibrinogen.

Slide 17 · Partial thromboplastin time: What it evaluates

Assay principle

Kaolin activates contact factors; Cephalin provides a phospholipid substitute. Clot formation is timed after adding calcium.

Pathway interrogated

PTT assesses intrinsic and common pathways; Abnormal factor activity or inhibitors may prolong the result.

Slide 18 · Why PT and PTT may remain normal

Platelet depletion

The blood contains too few circulating platelets.

Plasma factor function

The tested coagulation factors may remain intact.

Normal PT/PTT

Clotting times can be normal despite impaired primary hemostasis.

Slide 19 · An abnormal automated count needs smear confirmation

Electronic count

An anticoagulated blood sample is assessed by particle counting.

Peripheral blood smear

Inspect platelets directly and look for clumps.

Count interpretation

Only then decide whether the result represents true thrombocytopenia.

Slide 20 · Platelet clumping can simulate thrombocytopenia

Aggregation in sample

Platelets clump during automated laboratory analysis.

Analyzer undercount

Aggregates may be excluded from the platelet-sized particle population.

Spurious result

The reported platelet count can be artifactually low.

Slide 21 · Platelet-function tests: Selective utility

Aggregation testing

Assesses platelet interaction in response to agonists, including thrombin.

Von Willebrand factor assays

Quantitative and qualitative studies investigate a protein important for platelet adhesion.

Methodological limitation

No single assay reproduces all complex platelet functions or predicts bleeding reliably.

Slide 22 · A purpuric rash does not prove thrombocytopenia

Platelet-related hemorrhage

Numerical platelet depletion commonly presents with skin and mucosal bleeding; The platelet count is reduced.

Vessel wall disorders

Vascular fragility or vasculitis may produce petechiae and purpura while platelet counts and PT/PTT remain normal.

Slide 23 · Four mechanisms produce a low platelet count

1 — Reduced production

The marrow makes fewer platelets because general hematopoiesis or megakaryocyte output is impaired.

2 — Shortened survival

Immune removal, systemic consumption, or mechanical injury reduces platelet lifespan.

3 — Sequestration

An enlarged spleen retains a greater fraction of the circulating platelet pool.

4 — Dilution

Massive transfusion can decrease circulating platelet concentration.

Slide 24 · The platelet count reflects a dynamic balance

Marrow output

Production contributes platelets to the circulating pool.

Distribution

A portion of the platelet mass resides within the spleen.

Survival / consumption

Removal and use influence how long platelets remain available.

Slide 25 · Two routes to diminished platelet production

Global marrow impairment

Reduced overall hematopoietic output may be associated with aplastic anemia, leukemia, marrow replacement, or other marrow disorders.

Selective megakaryocyte impairment

Drug exposure, alcohol, HIV, and certain marrow abnormalities can preferentially decrease platelet production.

Slide 26 · Aplastic anemia: Low output across marrow lineages

Marrow failure can reduce production of platelets

Aplastic anemia is an example of reduced marrow output classification. Platelet depletion can coexist with failure of other cell lineages, because the underlying problem is not limited to circulating platelet destruction.

Mechanism: Inadequate marrow production

Slide 27 · Leukemia and marrow replacement

Replacement of normal hematopoiesis limits platelet generation

Leukemia, disseminated cancer, and granulomatous disease are listed among causes of decreased platelet production. The unifying principle is interference with the marrow compartment that ordinarily produces circulating blood cells.

Mechanism: Disrupted platelet production

Slide 28 · Selective megakaryocyte suppression

Exposure / infection

Certain drugs, alcohol, or HIV affect megakaryocyte output.

Megakaryocyte impairment

Platelet production falls without requiring initial peripheral consumption.

Thrombocytopenia

Fewer new platelets enter the circulating pool.

Slide 29 · Drug and alcohol exposure can decrease output

Alcohol and selected drugs

Alcohol, thiazides, and cytotoxic agents among exposures associated with platelet-production impairment.

Mechanistic qualification

For some agents, particularly high-dose exposures, selective megakaryocyte suppression is described but the mechanism remains uncertain.

Slide 30 · Infections may affect platelet production

HIV

Possible infection of megakaryocytes by HIV with inhibition of platelet production. HIV is also listed among causes of shortened platelet survival.

Measles

Listed in the etiologic table as an infection associated with decreased platelet production. The excerpt does not detail its cellular mechanism.

Slide 31 · Nutritional deficiencies impair platelet formation

Vitamin B12

Vitamin B12 deficiency is included among nutritional causes of decreased platelet production, in the setting of ineffective hematopoiesis.

Folate

Folate deficiency is also included; The diagnostic assessment should consider nutritional impairment as a production mechanism.

Slide 32 · Myelodysplastic neoplasms can present with thrombocytopenia

Ineffective hematopoiesis can be the primary problem

The classification includes myelodysplastic neoplasms among causes of reduced platelet output. Some cases may present with isolated thrombocytopenia, which can resemble peripheral platelet destruction.

An isolated low count does not prove an immune mechanism.

Slide 33 · Reduced production: A mechanism-based inference

Low platelet count

Confirm the abnormality on the peripheral smear.

Search for marrow causes

Consider aplasia, replacement, cytotoxic effects, nutritional deficits, and ineffective hematopoiesis.

Interpret the pattern

Decide whether generalized or selective production impairment is plausible.

Slide 34 · Shortened platelet survival: Two distinct routes

Immunologic

Antibodies or immune complexes become deposited on platelets and promote immune-mediated removal.

Nonimmunologic

Consumption during systemic thrombus formation or mechanical injury shortens circulating platelet survival.

Slide 35 · Immunologic thrombocytopenia: Causal sequence

Antibody association

Antibodies or immune complexes bind to platelet surfaces.

Immune recognition

Coated platelets are recognized as targets for removal.

Accelerated clearance

Platelet survival falls and the circulating count decreases.

Slide 36 · Autoimmune thrombocytopenia: Primary versus secondary

Primary ITP

The adjacent section describes autoantibody-mediated destruction when no predisposing cause is identified after evaluation.

Secondary immune thrombocytopenia

Can occur with systemic lupus erythematosus, HIV infection, and B-cell lymphoid neoplasms.

Slide 37 · Posttransfusion alloimmune thrombocytopenia

Allogeneic exposure

A transfusion exposes the recipient to platelets with differing antigens.

Antibody response

An alloimmune mechanism targets platelet antigens.

Platelet depletion

Immune-mediated shortened platelet survival can follow.

Slide 38 · Maternal–fetal alloimmune platelet destruction

Fetal platelet antigens

Platelets cross from the fetus into the maternal circulation.

Maternal IgG production

The mother generates antibodies recognizing the fetal platelet antigen.

Fetal thrombocytopenia

Maternal IgG can cause clinically important fetal platelet depletion.

Slide 39 · Immune platelet destruction: Representative associations

Drug-associated

Quinidine, heparin, and sulfa compounds are listed table.

Autoimmune / lymphoid

Chronic or acute immune thrombocytopenia; Lupus; B-cell lymphoid neoplasms.

Infection-associated

HIV, infectious mononucleosis (often transient and mild), and dengue fever.

Slide 40 · Heparin-associated platelet loss needs mechanistic care

Low platelet count does not imply a single bleeding-only syndrome

Heparin among drug-associated immunologic causes. Its adjacent dedicated section distinguishes clinically minor early platelet reductions from an immune syndrome associated with thrombosis.

Avoid inferring the specific mechanism from the drug history alone.

Slide 41 · HIV appears in more than one causal category

Production

HIV may infect megakaryocytes and inhibit the generation of new platelets.

Survival

HIV is also listed among infectious conditions associated with immune platelet destruction.

Slide 42 · DIC can consume circulating platelets

Systemic hemostatic activation

Disseminated intravascular coagulation produces extensive clotting activity.

Ongoing platelet use

Platelets are consumed in widespread intravascular processes.

Shortened survival

Circulating platelet numbers fall as consumption exceeds supply.

Slide 43 · Thrombotic microangiopathy consumes platelets

Small-vessel thrombosis

Excessive platelet activation generates thrombi in microvessels.

Platelet consumption

Platelets are incorporated into multiple microvascular thrombi.

Thrombocytopenia

Intravascular use reduces the circulating platelet pool.

Slide 44 · TMA is not synonymous with DIC

TMA

Platelet-rich microvascular thrombi are central; PT/PTT are usually normal because primary coagulation-cascade activation is not the driver.

DIC

The textbook groups DIC under consumptive causes but distinguishes its pathogenesis from that of thrombotic microangiopathies.

Slide 45 · Mechanical and vascular associations

Prosthetic heart valves

Mechanical platelet injury can shorten platelet survival in individuals with prosthetic valves.

Giant hemangiomas

Listed among nonimmune platelet-destructive associations in the chapter table; The excerpt does not specify an additional mechanism.

Slide 46 · Immunologic versus nonimmunologic survival loss

Dimension

Immunologic survival loss

Nonimmunologic survival loss

Proximal driver

Antibodies or immune complexes

Platelet consumption / mechanical injury

Representative contexts

ITP, alloimmunity, drugs, infections

DIC, TMA, prosthetic valves

Shared endpoint

Reduced circulating platelet lifespan

Reduced circulating platelet lifespan

Slide 47 · The normal splenic platelet pool

30–35%

Fraction normally sequestered

The spleen physiologically sequesters about one third of the body’s platelets. This distributional reserve is part of normal platelet kinetics and should not be mistaken for pathological destruction.

Slide 48 · Splenomegaly can greatly increase sequestration

80–90%

Fraction with enlarged spleen

When the spleen enlarges, the fraction of platelets sequestered there may rise dramatically. This shift can lower circulating platelet numbers and commonly produces moderate thrombocytopenia.

Slide 49 · Hypersplenism: A distributional mechanism

Enlarged spleen

The capacity for pooling platelets increases.

Greater splenic sequestration

A larger proportion of body platelets becomes retained.

Moderate thrombocytopenia

Fewer platelets remain measurable in peripheral circulation.

Slide 50 · Massive transfusion can cause dilutional thrombocytopenia

Major transfusion

Blood-product replacement alters blood composition and volume.

Platelet dilution

The concentration of circulating platelets decreases.

Measured low count

Thrombocytopenia reflects the dilutional mechanism.

Slide 51 · Four causes: Mechanism and representative clues

Mechanism

Key defect

Source examples

Reduced production

Insufficient marrow output

Aplasia, leukemia, alcohol, MDS

Reduced survival

Destruction or consumption

Immune loss, DIC, TMA, valve injury

Sequestration

Expanded splenic pooling

Splenomegaly / hypersplenism

Dilution

Lower platelet concentration

Massive transfusion

Slide 52 · Interpret a low platelet count by the mechanism

Confirm the count

Review the smear for platelet clumps.

Assess hemostasis

Interpret PT and PTT and recognize the bleeding pattern.

Classify the cause

Investigate production, survival, sequestration, or dilution.

Slide 53 · Clinical reasoning 1 — mucocutaneous bleeding

CLINICAL VIGNETTE

An adult has gingival bleeding and petechiae. The platelet count is markedly reduced; PT and PTT are normal. The blood smear confirms a true low platelet number.

Which hemostatic component is implicated first?

Interpretation: A platelet-number disorder is plausible; Normal PT/PTT do not establish the etiology.

Slide 54 · Clinical reasoning 2 — a marrow-centered clue

CLINICAL VIGNETTE

A patient has thrombocytopenia in the setting of a disorder that substantially depresses marrow hematopoiesis.

Which broad category explains the low count?

Interpretation: Decreased platelet production from generalized marrow impairment.

Slide 55 · Clinical reasoning 3 — an enlarged spleen

CLINICAL VIGNETTE

A patient with marked splenomegaly has a moderately reduced circulating platelet count.

Which mechanism should be considered?

Interpretation: Increased splenic sequestration may account for moderate thrombocytopenia.

Slide 56 · Clinical reasoning 4 — a transfusion context

CLINICAL VIGNETTE

A patient undergoing massive transfusion develops a falling peripheral platelet count.

Which additional category enters the differential?

Interpretation: Dilutional thrombocytopenia is a recognized mechanism.

Slide 57 · Clinical reasoning 5 — microvascular thrombosis

CLINICAL VIGNETTE

A patient with thrombocytopenia also has evidence of widespread small-vessel platelet-rich thrombi.

Which process can consume circulating platelets?

Interpretation: A thrombotic microangiopathic process promotes platelet consumption.

Slide 58 · A practical four-branch causal map

Low platelet output

Marrow failure, impairment, replacement, or ineffective hematopoiesis.

Short platelet survival

Immune removal, consumption, or mechanical injury.

Altered distribution

Splenic sequestration in splenomegaly.

Altered concentration

Dilution after massive transfusion.

Slide 59 · High-yield synthesis

Recognize the phenotype

Thrombocytopenia favors small-vessel, skin, and mucosal bleeding; Profound depletion risks spontaneous and intracranial hemorrhage.

Validate the count

Confirm suspicious automated results on a peripheral blood smear before assigning an etiology.

Do not misread coagulation tests

PT and PTT can remain normal in isolated thrombocytopenia and in some consumptive microangiopathies.

Classify the causal pathway

Production, survival, sequestration, and dilution supply the organizing framework for subsequent diagnosis.

Slide 60 · References and scope

Primary reference

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th edition (2026). Chapter 14, Red Blood Cell and Bleeding Disorders.

Core reading: Bleeding Disorders: Hemorrhagic Diatheses; Thrombocytopenia (pp. 602–604). Contextual sections: immune thrombocytopenia and thrombotic microangiopathies (pp. 604–606).